Dr. Aaron H. Bubolz, D.O.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Des Moines University of Osteopathic Medicine and Health Sciences (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 60
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Des Moines University of Osteopathic Medicine and Health Sciences
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
WI license 65891
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Froedtert Memorial Lutheran Hospital Milwaukee, WI
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 60
- Services billed
- 12,522
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 5,000 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 69 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Emgality Pen (galcanezumab-gnlm) Other prescribers in Green Bay, WI | 44 |
| Butalbital-Acetaminophen-Caffe (butalb/acetaminophen/caffeine) Other prescribers in Green Bay, WI | 42 |
| Ubrelvy (ubrogepant) Other prescribers in Green Bay, WI | 39 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Green Bay, WI | 38 |
| Qulipta (atogepant) Other prescribers in Green Bay, WI | 34 |
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in Green Bay, WI | 34 |
| Nurtec Odt (rimegepant sulfate) Other prescribers in Green Bay, WI | 32 |
| Naratriptan Hcl | 30 |
| Tizanidine Hcl Other prescribers in Green Bay, WI | 27 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Green Bay, WI | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 67 payments worth $10,691 in total to this clinician.
| AbbVie Inc. | $7,397 |
|---|---|
| Pfizer Inc. | $2,859 |
| Axsome Therapeutics, Inc. | $304 |
| Lundbeck LLC | $81.23 |
| Teva Pharmaceuticals USA, Inc. | $35.14 |
| Lilly USA, LLC | $14.36 |
| Compensation for services other than consulting (speaking, faculty) | $7,651 |
|---|---|
| Consulting Fee | $1,525 |
| Food and Beverage | $1,514 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $2,625 |
| AbbVie Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $2,625 |
| Pfizer Inc. Sep 25, 2025 | Consulting Fee NURTEC ODT · PAIN | $1,525 |
| Pfizer Inc. Oct 15, 2025 | Compensation for services other than consulting (speaking, faculty) ZAVZPRET · PAIN | $1,220 |
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,181 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 2 companies. The companies reported $514,735 in research payments for these studies, mostly to the institutions running them.
- A phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult par…
AstraZeneca UK Limited - A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult …
AbbVie Inc. - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - The purpose of this study is to evaluate mass balance pharmacokinetics and safety of [14C] ABBV-552 in healthy male volunteers following administration of a single oral dose
AbbVie Inc. - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie Inc. · Enrolling by invitation · NCT05127954 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.